Physician profile
Joji James
NPI 1134534571
$1,615.92
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.97 · 2023: $276 · 2024: $1,020 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.35 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.92 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $205.13 | 2024-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $188.97 | 2024 | |
| Novartis Pharmaceuticals Corporation | $184.36 | 2023-2025 | |
| Travere Therapeutics, INC. | $121.09 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $102.32 | 2023-2025 | Tarpeyo |
| Amgen INC. | $89.60 | 2024 | Krystexxa |
| Lilly USA, LLC | $60.48 | 2023-2024 | Trulicity, Mounjaro, Jardiance |
| Novo Nordisk INC | $58.89 | 2024-2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $49.73 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $28.80 | 2024 | Oxlumo |
| Corcept Therapeutics | $24.92 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.47 | 2023 | Xifaxan |
| Radius Health, INC. | $21.29 | 2025 | Tymlos |
| Cequr Corporation | $20.17 | 2023 | Cequr Simplicity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.13 | 2024 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $19.34 | 2023 | |
| Exact Sciences Corporation | $18.41 | 2025 | The Cologuard Plus Collection Kit |
| Opko Pharmaceuticals, LLC | $17.49 | 2023 | Rayaldee |
| Esperion Therapeutics, INC. | $15.95 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $14.94 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.69 | 2024 | Airsupra |
| Embecta Corp. | $12.83 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joji James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.